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s u m m a r y 
Objectives: Data on meningitis epidemiology in high HIV-prevalence African settings following antiretro- 
viral therapy scale-up are lacking. We described epidemiology of adult meningitis in Botswana over a 
16-year period. 
Methods: Laboratory records for adults undergoing lumbar puncture (LP) 20 0 0–2015 were collected, with 
complete national data 2013–2014. Cerebrospinal ﬂuid (CSF) ﬁndings and linked HIV-data were described, 
and national incidence ﬁgures estimated for 2013–2014. Temporal trends in meningitis were evaluated. 
Results: Of 21,560 adults evaluated, 41% (8759/21,560) had abnormal CSF ﬁndings with positive microbi- 
ological testing and/or pleocytosis; 43% (3755/8759) of these had no conﬁrmed microbiological diagno- 
sis. Of the 5004 microbiologically-conﬁrmed meningitis cases, 89% (4432/5004) were cryptococcal (CM) 
and 8% (382/5004) pneumococcal (PM). Seventy-three percent (9525/13,033) of individuals undergoing 
LP with identiﬁers for HIV registry linkage had documented HIV-infection. Incidence of LP for meningi- 
tis evaluation in Botswana 2013–2014 was 142.6/10 0,0 0 0 person-years (95%CI:138.3–147.1); incidence of 
CM was 25.0/10 0,0 0 0 (95%CI:23.2–26.9), and incidence of PM was 2.7/10 0,0 0 0 (95%CI:2.4–3.1). In con- 
trast to previously reported declines in CM incidence with ART roll-out, no signiﬁcant temporal decline 
in pneumococcal or culture-negative meningitis was observed. 
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Conclusions: CM remained the predominant identiﬁed aetiology of meningitis despite ART scale-up. A 
high proportion of cases had abnormal CSF with negative microbiological evaluation. 
© 2019 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
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Introduction 
Central nervous system (CNS) infections are a major cause of 
morbidity and mortality in people living with HIV (PLWH). 1 Stud- 
ies in high HIV prevalence regions of central, east, and southern 
Africa have shown cryptococcal, TB, and pneumococcal meningitis 
to be the most common microbiologically-conﬁrmed etiologies of 
meningitis. 2–5 However, these studies have generally been limited 
to single referral centres, 2,3,5 or have used sub-national surveil- 
lance data, 4 and data regarding temporal trends in meningitis 
with ART scale-up and vaccine introduction are limited. Nationally- 
representative longitudinal data of meningitis under routine care 
conditions can provide important insights into the shifting epi- 
demiology of CNS infections in sub-Saharan Africa (SSA), highlight 
limitations of current diagnostic strategies, and inform research on 
approaches to improve management for CNS infections. 
Botswana, a middle-income country in southern Africa with 
a 23% adult HIV prevalence in 2017, 6 established the ﬁrst an- 
tiretroviral therapy (ART) program in Africa in early 2002 with 
public sector care delivered free-of-charge to citizens. Expanded 
access to ART has led to high coverage, with more than 70% of 
PLWH estimated to have been diagnosed, started on ART, and 
virologically suppressed. 7 Despite progress, late presentation with 
advanced HIV/AIDS, 8,9 as well as care default, 10 are common. 
We previously showed ongoing high incidence of HIV-associated 
cryptococcal meningitis in Botswana despite excellent ART cov- 
erage. 11 Incidence and temporal trends for other HIV-associated 
meningitides have not been described, including potential changes 
in pneumococcal meningitis following the 2012 introduction of 
childhood 13-valent pneumococcal conjugate vaccine (PCV13). 12 
In a nationwide meningitis study, we collected laboratory 
records at all facilities that performed microbiological testing of 
cerebrospinal ﬂuid (CSF). We characterized cases over a 16-year 
period (20 0 0–2015) in adults ( ≥15 years old), determined national 
incidence of meningitis during 2013–2014 when full national lab- 
oratory data were available, and examined temporal trends over 
an 11-year period at Botswana’s two referral hospitals (2004–2014) 
when full records were available at these centres. 
Methods 
Study design and data collection 
A cross-sectional study was performed using data from the 
Botswana National Meningitis Survey (BNMS), as described previ- 
ously but extended through 2015. 11 BNMS included records from 
laboratory facilities that perform cerebrospinal ﬂuid (CSF) test- 
ing for meningitis evaluation. Data sources included paper-based 
records collected during in-person laboratory visits and records 
from electronic medical records (EMRs) used during the study 
period. Records were merged and de-duplicated. 
Standard CSF evaluation, following national laboratory proto- 
cols, remained unchanged during the study period and consisting 
of white cell count (WCC) and differential (lym phocytes, neu- 
trophils) when WCC ≥10 cells/μL, protein and glucose, microscopy 
(gram stain, India ink), and bacterial and fungal culture. 13 The 
full work-up was incomplete for some patients (e.g. missing WCC, 
protein, or glucose), due to reagent stockout or incomplete lab- 
oratory recording. CSF latex agglutination cryptococcal antigen 
(CrAg) testing was performed infrequently. Tuberculous menin- 
gitis evaluation by acid-fast bacillus (AFB) [Ziehl-Neelsen] smear 
was performed in some laboratories, on request, with TB culture 
available as a send-out to a national reference laboratory (National 
Tuberculosis Reference Laboratory). XPert MTB/RIF was introduced 
in 2012 but was not used on CSF samples. Other molecular di- 
agnostic testing (e.g. herpes simplex viruses or Toxoplasma gondii 
PCR) and syphilis testing have not been introduced in public-sector 
laboratories. 
HIV-related data (HIV status, CD4 count, ART use) were ob- 
tained from EMR records and from a national HIV registry through 
deterministic linkage of laboratory and HIV records using a unique 
9-digit national identiﬁcation number (“Omang”). As Omang was 
not documented in paper records, linkage was restricted to individ- 
uals undergoing evaluations at centres using the EMR, Integrated 
Patient Management System (IPMS). For CD4 T-cell count, the clos- 
est value within a 6-month period of lumbar puncture (LP) was 
used. Prior ART use was deﬁned as documented prescription of 
ART or any HIV viral load testing within 3 months of CSF evalua- 
tion (as initial viral load testing only occurs after at least 3 months 
on ART 14 ). 
The study was approved by the University of Botswana, the 
Botswana Ministry of Health and Wellness’ Health Research Devel- 
opment Committee, Botswana referral and district hospitals with 
research ethics committees, the University of Pennsylvania, and the 
University of Washington. 
Case deﬁnitions 
A “case,” or episode, was deﬁned as receipt of a LP with CSF 
analysis at any lab in Botswana from 20 0 0 to 2015. We restricted 
our analysis to adults ( ≥15-years) because of differences in the HIV 
prevalence and epidemiology of CNS infections in adults and chil- 
dren, and for consistency with age strata in UNAIDS denominator 
estimates. Cases were characterized by microbiological diagnosis: 
Cryptococcal meningitis was deﬁned as positive CSF microscopy 
(India ink), culture, and/or CrAg. TB meningitis was deﬁned as 
positive CSF culture for Mycobacterium tuberculosis or AFB smear. 
Two deﬁnitions were used for pneumococcal meningitis: A restric- 
tive deﬁnition limited to individuals with CSF culture growth of S. 
pneumoniae , and a second including positive CSF culture or gram 
stain showing gram-positive cocci. This deﬁnition was used due 
to imperfect sensitivity of culture and added diagnostic yield of 
gram stain, 15,16 particularly in patients receiving pre-LP antibiotics. 
Other meningitides were deﬁned by positive CSF culture. 
Cases without positive microbiological test results (microscopy, 
culture, and/or CrAg) were deﬁned as normal (CSF WCC 0–
5 cells/μL), with minor abnormalities (WCC 6–20 cells/μL), or 
markedly abnormal (WCC > 20 cells/μL), the latter stratiﬁed as lym- 
phocytic ( ≥50% lymphocytes) or neutrophilic ( < 50% lymphocytes). 
CSF protein and glucose analyses were not performed in a sizeable 
proportion of samples, thus additional classiﬁcations of culture 
negative-disease were not explored. To account for repeated LPs 
(e.g. therapeutic LPs for cryptococcal meningitis), all CSF evalua- 
tions within a ≤14-day window from a previous LP were deﬁned 
as part of the same episode, and results from the ﬁrst LP used in 
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21,560 
episodes
3,220 CSF WCC missing & no 
microbiological diagnosis
9,581 no CSF abnormality & 
no microbiological diagnosis
1,309 minor abnormalies,
no posive microbiology
8,759 abnormal CSF 
and/or microbiological 
diagnosis
5,004 with posive microbiology*
Cryptococcus 4432 (89%)
Bacterial 552 (11%)
TB 51 (1%)
2,446 markedly abnormal,
no posive microbiology
Lymphocyc 1,348 (55%)
Pyogenic 632 (26%)
No diﬀerenal 466 (19%)
Fig. 1. Overall description of 21,560 adult cases. Of 34,505 overall lumbar puncture assessments, 7238 samples from children, 4014 with undocumented age, and 1693 repeat 
lumbar punctures excluded. Having minor abnormalities was deﬁned as a CSF WCC 6–20 cells/μl; markedly abnormal CSF was deﬁned as a WCC > 20 cells/μL. 
CSF - cerebrospinal ﬂuid; TB - tuberculosis; WCC - white cell count 
∗> 100 percent due to 31 mixed cryptococcal and bacterial meningitis cases and 2 mixed cryptococcal and TB meningitis; 1 additional case of Candida spp and 1 non- 
tuberculous Mycobacterium without further speciation also found. 
the analysis. For TB meningitis, LP evaluations within a 6-month 
window of diagnosis were considered part of a single episode. 
Data analysis 
Findings from all adult cases 20 0 0–2015 were described, in- 
cluding proportion of cases with positive microbiological ﬁndings 
and classiﬁcation of cases without positive microbiological ﬁnd- 
ings by WCC strata. Patient demographic, HIV clinical character- 
istics, and CSF ﬁndings were evaluated using descriptive statistics 
(number and percentage or median and interquartile range [IQR]). 
Complete CSF records were obtained from all laboratories in 
Botswana 2013–2014. During this two-year period the overall and 
HIV-speciﬁc incidence of meningitis cases in adults ( ≥15 years) 
was determined by category (any LP, cryptococcal meningitis, 
pneumococcal meningitis, or markedly abnormal CSF [WCC > 20 
cells/μL] with or without positive bacterial gram stain or culture). 
TB meningitis incidence was not evaluated due to the small 
number of conﬁrmed cases resulting from limitations in TB diag- 
nostics. UNAIDS Spectrum data were used for national population 
denominator estimates. 11 Incidence estimates with 95% conﬁdence 
intervals (95% CIs) were calculated using a Poisson distribution. 
To account for missing age in a small proportion of cases (3%), 
when deriving incidence estimates it was assumed that the age 
distribution (adult vs. child) was the same in cases without doc- 
umented age as in those with age data for each type of meningitis. 
The total number of HIV-associated cases for each meningitis type 
was estimated by applying the HIV prevalence data derived from 
the cases registered in IPMS and linked the HIV database to the en- 
tire cohort. This provides a conservative estimate of HIV-associated 
cases as some PLWH may have been undiagnosed. 
At referral hospitals with complete longitudinal records 2004–
2014 the number of cases were plotted by year to evaluate trends 
in cryptococcal, pneumococcal, and culture-negative meningitis 
with pleocytosis (including CSF WCC 6–20/μL and > 20/μL). Due to 
the lack of deﬁned catchment populations for the two referral hos- 
pitals, it was not possible to statistically evaluate incidence trends. 
Rather, given consistent clinical care provision and referral path- 
ways over the full study duration (as evidenced by a consistent 
proportion of cases seen at the two referral hospitals), univariate 
Poisson regression was used to assess trends in case numbers 
over time. Finally, seasonality of culture-conﬁrmed pneumococcal 
meningitis cases was assessed by plotting number of cases by cal- 
endar month (January, February, etc.), along with average Botswana 
temperature and rainfall by month 20 0 0–2015. 17 Both adult and 
paediatric cases were included for seasonality evaluation as similar 
ﬁndings were observed for both groups. We did not perform a 
time-series analysis for seasonality due to the small number of 
cases per month. Analyses were performed in Stata (Version 13, 
College Station, TX) and ﬁgures generated using Stata and the 
ggplot2 package in R. 18 Statistical signiﬁcance was deﬁned as a 
p-value < 0.05. 
Results 
Overall description of cases 
A total of 34,505 LP samples were documented from 20 0 0 to 
2015. After restricting to adults ( ≥15 years), and excluding repeat 
samples, 21,560 unique cases were observed ( Fig. 1 ). Fifty-six 
percent (12,143/21,560) were from referral hospitals. Median age 
was 36 years (IQR 30–45) and 52% (11,108/21,488) were male. 
Forty-one percent (8759/21,560) had at least minor CSF WCC 
abnormalities and/or positive microbiological ﬁndings. A microbio- 
logical diagnosis was made in 23% (5004/21,560) of cases. Of those 
with HIV-related information, 73% (9525/13,033) were known to 
be HIV-infected. Median CD4 count was 91 cells/μL (IQR 37–216) 
with 47% (4474/9525) initiated on ART prior to the date of LP. 
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Table 1 
Clinical and laboratory characteristics of patients evaluated for meningitis. 
Pathogen Age (years), 
Median (IQR) 
Sex,% (n) 
male 
CSF WCC (/μL), 
median (IQR) ∗
Lymphocyte% 
(IQR) 
Protein (g/dL), 
median (IQR) 
Glucose, 
mmol/L, 
median (IQR) 
HIV + ve,% 
(n/N) † 
CD4 count 
(cells/μL) if HIV 
+ ve, median (IQR) 
On ART if HIV 
+ ve,% (n) 
With microbiological diagnosis 
Cryptococcus 
( n = 4432) 
36 (31–43) 61.5% 
(2720/4421) 
5 (2–34) 90% (60–95) 0.91 
(0.49–1.75) 
2.10 
(1.23–2.86) 
99.9% 
(2772/2775) 
42 (19–89) 37.5% 
(1039/2772) 
TB 
( n = 51) 
36 (31–45) 54.9% (28/51) 48 (8–150) 90% (20–96) 2.56 
(0.93–3.27) 
0.83 
(0.61–1.36) 
82.8% (24/29) 104 (27–165) 20.8% (5/24) 
Pneumococcus 
( n = 382) 
36 (30–45) 43.2% 
(164/380) 
250 (40–946) 10% (5–24) 3.66 
(2.42–6.66) 
0.07 
(0.01–0.90) 
61.5% 
(150/244) 
196 
(127–379) 
39.3% (59/150) 
Without microbiological diagnosis 
CSF WCC 0–5 
( n = 9581) 
36 (30–46) 47.6% 
(4546/9557) 
—- —- 0.47 
(0.26–0.92) 
3.20 
(2.60–3.85) 
66.2% 
(4052/6119) 
113 (44–268) 54.5% 
(2207/4052) 
CSF WCC 6–20 
( n = 1309) 
36 (30–45) 50.2% 
(654/1302) 
—- —- 0.84 
(0.40–1.80) 
2.84 
(2.00–3.72) 
66.8% 
(514/770) 
129 (55–254) 52.0% 
(267/514) 
CSF WCC > 20, 
no differential 
( n = 466) 
36 (30–45) 53.7% 
(249/464) 
70 (32–230) —- 1.58 
(0.80–3.18) 
2.10 
(1.12–3.17) 
64.8% 
(136/210) 
138 (69–317) 46.3% 
(63/136) 
CSF WCC > 20, 
lymphocytic 
( n = 1348) 
36 (29–43) 52.6% 
(708/1345) 
123 (54–312) 90% (80–96) 1.83 
(1.00–3.53) 
1.92 
(1.10–2.89) 
70.7% 
(662/936) 
156 (77–284) 48.0% 
(318/662) 
CSF WCC > 20, 
pyogenic 
( n = 632) 
36 (30–44) 57.1% 
(358/627) 
244 (75–810) 15% (9–30) 2.37 
(1.18–4.21) 
1.46 
(0.90–2.43) 
60.1% 
(217/361) 
116 (53–214) 43.3% (94/217) 
+ ve - positive; ART - antiretroviral therapy; IQR - interquartile range; WCC - white cell count. 
∗ Upper limit recorded for WCC 20 0 0/μL. 
† Among patients with documented HIV status. 
Characteristics by pathogen 
Cryptococcal meningitis (CM) accounted for the majority of 
cases with positive microbiological ﬁndings (89%, 4432/5004). Al- 
though India ink and culture was performed routinely on all CSF 
samples, CrAg testing was performed in only 9% (1844/21,560) of 
episodes. Most CM patients were males (62%, 2720/4421) ( Table 1 ), 
with mild CSF inﬂammation (median WCC 5/μL [IQR 2–34]). Nearly 
all with HIV registry linkage were known HIV-infected ( > 99.9%, 
2772/2775), with a median CD4 count of 42 cells/μL (IQR 19–89) 
and 38% (1039/2772) already taking ART. 
TB meningitis (TBM) was diagnosed in 1% (51/5004) of cases 
with positive microbiological ﬁndings; 36 by culture, 14 by AFB 
smear, and 1 by both. This was in the context of infrequent evalu- 
ation for TB, with smear performed in 22% (4755/21,560) and cul- 
ture in 7% (1517/21,560) of cases. CSF was characterized by mod- 
erate lymphocytic pleocytosis but signiﬁcant spread (median WCC 
48/μL [IQR 8–150]). Most patients with available HIV-related data 
were known HIV-infected (83%, 24/29), with a median CD4 count 
of 104 cells/μL (IQR 27–165). 
Cases with conﬁrmatory bacterial culture and/or gram stain ac- 
counted for 11% (552/5004) of those with positive microbiologi- 
cal ﬁndings; 72% (395/552) of these were culture-positive and 28% 
(157/552) had a positive gram stain alone. Pneumococcal meningi- 
tis was identiﬁed in 69% (382/552), 73% (278/382) of whom were 
S. pneumoniae culture-positive. Pneumococcal meningitis cases 
showed highly inﬂammatory neutrophil-predominant pleocytosis 
and hypoglycorrhachia; 62% with HIV-related data (150/244) were 
known HIV-infected with a median CD4 count of 196 cells/μL (IQR 
127–379). CSF and clinical characteristics were similar when we re- 
stricted to culture-conﬁrmed cases alone ( Supplemental Table 1 ). 
Other typical bacterial pathogens were uncommon: 11 
Haemophilus inﬂuenzae , 6 Group B Streptococcus , 1 Neisseria 
meningitidis , and 1 Listeria monocytogenes cases. Other cultured 
isolates included 34 Enterobacteriaceae (14 Klebsiella pneumoniae , 
13 Escherichia coli , 4 Salmonella spp , 2 Enterobacter spp, 1 Proteus 
mirabilis ), 32 Staphylococcus spp (20 coagulase-negative Staphy- 
lococcus , 12 Staphylococcus aureus ), 15 non-pneumococcal and 
non-group B Streptococcus spp , 3 Pseudomonas aeruginosa cases, 
and 12 with other pathogens. Clinical data to distinguish likely 
contamination versus clinical disease for atypical pathogens, e.g. 
coagulase-negative Staphylococci , were unavailable. 
Cases with negative microbiological evaluation 
Seventy-seven percent (16,556/21,560) of LP evaluations for 
meningitis had no positive microbiological ﬁndings ( Fig. 1 ), of 
which 19% (3220/16,556) had no CSF WCC recorded. Of cases with 
WCC, 28% (3755/13,336) showed elevated WCC; 10% (1309/13,336) 
mildly abnormal (6–20 cells/μL) and 18% (2446/13,336) markedly 
abnormal ( > 20 cells/μL), the majority with lymphocyte predomi- 
nance (55% [1348/2446]) in those with a WCC differential. Demo- 
graphic and HIV-related characteristics were similar between WCC 
categories. Of all cases with negative evaluation, 66% (6526/9897) 
with HIV registry linkage were known HIV-infected with a median 
CD4 count of 120 cells/mL (IQR 49–269) and 51% (3343/6526) were 
on ART before evaluation. 
National incidence and temporal trends 
Over the two-year period with complete national data (2013–
2014), an estimated 142.6 LPs / 10 0,0 0 0 person-years (95%CI: 
138.3–147.1) were performed in adults overall, and 405.7 LPs 
/10 0,0 0 0 person-years (95%CI: 391.6–420.1) among those known 
to be HIV-infected ( Table 2 ). Using the combined deﬁnition 
for pneumococcal meningitis (positive CSF culture and/or gram 
stain), the estimated overall incidence of pneumococcal menin- 
gitis was 2.7/10 0,0 0 0 person-years (95%CI: 2.4–3.1) and 5.9 
/10 0,0 0 0 person-years (95%CI: 4.3–7.9) in the HIV-infected pop- 
ulation. Restricted to culture-conﬁrmed pneumococcal meningi- 
tis, incidence was 1.8 /10 0,0 0 0 person-years (95%CI: 1.4–2.4) over- 
all and 4.3/10 0,0 0 0 person-years (95%CI: 2.9–6.0) among those 
known to be HIV-infected. Incidence of cryptococcal menin- 
gitis was 25.0/10 0,0 0 0 person-years (95%CI: 23.2–26.9) overall 
and 92.9/10 0,0 0 0 person-years (95%CI: 86.2–99.9) in HIV-infected 
adults. 
As previously described, 11 cases of cryptococcal meningi- 
tis declined from 2004 to 2014 at referral hospitals ( Fig. 2 ). 
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Table 2 
Botswana national incidence of adult ( ≥15 years) meningitis, 2013–2014. 
Strata Category Number of cases Person-years Incidence 
(per 10 0,0 0 0 PYO) 
95% conﬁdence interval 
(per 10 0,0 0 0 PYO) 
Underwent lumbar puncture Overall population 
Known HIV-infected 
4114 
3150 
2,884,278 
776,523 
142.6 
405.7 
138.3 - 147.1 
391.6 - 420.1 
Cryptococcal meningitis Overall population 
Known HIV-infected 
721 
721 
2,884,278 
776,523 
25.0 
92.9 
23.2 - 26.9 
86.2 - 99.9 
Pneumococcal meningitis 
( + ve culture or GPCs) 
Overall population 
Known HIV-infected 
73 
46 
2,884,278 
776,523 
2.7 
5.9 
2.4 - 3.1 
4.3 - 7.9 
Pneumococcal meningitis 
( + ve culture) 
Overall population 
Known HIV-infected 
53 
33 
2,884,278 
776,523 
1.8 
4.3 
1.4 - 2.4 
2.9 - 6.0 
Any abnormal CSF (WCC > 20 or 
non- Cryptococcus pathogen) 
Overall population 
Known HIV-infected 
313 
213 
2,884,278 
776,523 
10.9 
27.4 
9.7 - 12.1 
23.9 - 31.4 
+ ve - positive; CSF - cerebrospinal ﬂuid; GPC - gram positive cocci; WCC - white cell count. 
Fig. 2. Trends in meningitis cases at Botswana national referral hospitals, 2004–2014. 
WCC 6–20 cells/μL and > 20 cells/μL were used to reﬂect minor and marked inﬂammation of the CSF suggesting infection or other central nervous system pathology 
CSF - cerebrospinal ﬂuid; WCC - cerebrospinal ﬂuid white cell count 
Classiﬁcations for pneumococcal meningitis restricted to culture-positive cases. WCC > 20 and WCC 6–20 groups excluded cases of diagnosed cryptococcal meningitis. 
∗ Excluded 2006 data for Cryptococcus, WCC > 20 and WCC 6–20; a large drop in cryptococcal meningitis cases and concurrent rise in cases with WCC 6–20 and WCC > 20 
likely represented missed diagnoses of cryptococcal meningitis in this year. 
However, similar trends were not observed for pneumococcal cases 
( p = 0.68), cases with minor WCC abnormalities (6–20 cells/μL) 
[ p = 0.94], or cases with markedly abnormal CSF (WCC > 20 
cells/μL) [ p = 0.16]. No decrease in adult pneumococcal meningi- 
tis cases was observed 2013–2014 following childhood PCV13 in- 
troduction, compared to the earlier period, although based on a 
small number of cases from referral centres. In seasonal analysis 
of culture-conﬁrmed pneumococcal meningitis, cases peaked in the 
winter and early spring ( Fig. 3 ). 
Discussion 
Using a nationally representative sample of over 20,0 0 0 adult 
episodes of suspected meningitis over 16 years, this study pro- 
vides novel insights into the epidemiology of meningitis in high 
HIV-prevalence regions of Africa. About three-quarters of adult pa- 
tients evaluated for CNS infection were known to be HIV-infected. 
Evaluation for CNS infections was common in the HIV-infected 
adults, with over 400 LPs/100,000 person-years. Most HIV-infected 
individuals undergoing LP were profoundly immunocompromised 
(median CD4 < 100 cells/μL) despite almost half having a history 
of ART use. This mirrors ﬁndings from recent studies showing ap- 
proximately half of patients with cryptococcal meningitis are now 
ART-experienced, 19–21 reﬂecting a combination of late presentation 
to care with severe immune-suppression, 9 default from care, and 
ART failure from resistance. Interpreted alongside recent data 
showing that approximately half of patients with culture-negative 
suspected meningitis and two-thirds diagnosed with cryptococcal 
meningitis die within one year of presentation in Botswana, 13,22 
these ﬁndings demonstrate that CNS infections remain an impor- 
tant cause of mortality in HIV-infected individuals over a decade 
into the ART era. 
Our ﬁndings highlight severe limitations in routine strategies 
for the diagnosis of meningitis common throughout much of 
sub-Saharan Africa. Consistent with previous studies from South 
Africa, 3,4 Zambia, 23 and Uganda, 24 cryptococcal meningitis was the 
most common aetiology of meningitis accounting for about 90% of 
cases. This high case ascertainment reﬂects both the still-high bur- 
den of advanced HIV/AIDS and excellent diagnostic yield combin- 
ing rapid cryptococcal testing (usually India ink) with more sensi- 
tive fungal culture in all cases. Without use of the highly-sensitive 
CrAg lateral ﬂow assay (LFA) [IMMY, Norman, OK] in Botswana, 25 
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Fig. 3. (A) Culture-conﬁrmed pneumococcal meningitis cases, (B) average rainfall 
(centimetres), and (C) average temperature (Celsius) by month. 
∗ Month: 1 = January, 2 = February, etc.; the number of cases each month represent 
the total number of cases of pneumococcal meningitis diagnosed during the cal- 
endar month over the full observation period; graphed monthly temperature and 
rainfall also represent mean values observed during a calendar month over the full 
observation period. 
a small number of additional cases of cryptococcal meningitis may 
have been misclassiﬁed as having a negative diagnostic work-up. 
Given the poor sensitivity of India ink stain, LFA CrAg testing 
should be used as a preferred rapid diagnostic test for cryptococcal 
meningitis. 
Microbiological diagnoses other than cryptococcal meningitis 
were infrequent despite a signiﬁcant proportion of cases with ab- 
normal CSF WCC. TB accounted for only 1% of cases with positive 
microbiological ﬁndings. This contrasts with surveillance data from 
South Africa 2009–2012, where almost 25% of microbiologically- 
conﬁrmed adult meningitis cases had TB conﬁrmed by smear, 
culture and/or Xpert. Although the incidence of TB is lower in 
Botswana than in South Africa (estimated at 30 0/10 0,0 0 0 versus 
567/10 0,0 0 0, respectively, in 2017 26 ), a 25-times lower proportion 
of TB meningitis among patients being investigated for meningi- 
tis in Botswana compared to South Africa is unlikely. Of cases in 
Botswana with pleocytosis and/or a positive microbiological ﬁnd- 
ing, 15% (1348/8759) had a WCC > 20/μL with lymphocytic pre- 
dominance and negative standard work-up, much of which likely 
reﬂects undiagnosed TB meningitis. The small number of con- 
ﬁrmed TB diagnoses in Botswana almost certainly reﬂects infre- 
quent TB testing despite culture availability. Reasons for infrequent 
TB diagnostic testing are probably multifactorial, including lack 
of decentralized testing and intermittent TB laboratory stoppages; 
however a major factor driving clinicians’ low testing rates is likely 
the poor sensitivity of AFB smear and delays in culture results with 
lack of actionable data on which to base clinical decisions. 27 Pa- 
tients with TB meningitis and advanced immune suppression due 
to HIV also often lack signiﬁcant CSF pleocytosis or other “clas- 
sic” CSF ﬁndings, 28 possibly reducing clinical suspicion. Rapid next- 
generation Xpert (Ultra) has recently shown improved yield over 
CSF culture in HIV-infected Ugandan patients, 29 and gives action- 
able results within hours, providing an attractive diagnostic option 
for TB meningitis which may overcome many of the existing diag- 
nostic challenges and should be more widely implemented for the 
diagnostic work-up of meningitis. 30 
Bacterial meningitis accounted for 11% of cases with positive 
microbiological ﬁndings with a predominance of Streptococcus 
pneumoniae . Even using a conservative deﬁnition restricted to 
culture-conﬁrmed cases the adult national incidence of 1.8 cases 
/ 10 0,0 0 0 person-years is similar to a reported 2012 incidence of 
culture-conﬁrmed cases in Gauteng Province, South Africa of 2.5 
cases / 10 0,0 0 0 person-years but approximately 6 times higher 
than the rate estimated in the United States in 2010 4,31 (or 9 times 
higher with an expanded case deﬁnition combining culture and 
gram stain results). HIV-speciﬁc pneumococcal meningitis inci- 
dence was approximately 15–20-fold higher than in the general 
U.S. population. Our pneumococcal meningitis incidence estimates 
in Botswana are certainly an underestimate of true population 
rates. First, we found a large number of culture-negative cases 
with markedly elevated CSF white cell count ( > 20/μL) and neu- 
trophil predominance (632 cases versus 278 culture-conﬁrmed 
pneumococcal meningitis cases), probably in-part representing 
rapid CSF sterilization and decreased culture sensitivity with 
pre-LP antibiotic administration. 32 Pneumococcal meningitis oc- 
curred year-round but peaked during winter and early spring, as 
previously described. 33 Cases of pneumococcal meningitis over 
a > 10-year period at the two referral hospitals were largely 
unchanged over time and did not show any appreciable decline 
following introduction of PCV13 vaccination in 2012, although our 
analysis was restricted to just two full years following introduc- 
tion. Pneumococcal vaccination trials in HIV-infected adults in 
Africa have shown mixed results, 34,35 but paediatric vaccination 
may provide some protection through herd immunity, 36 and 
further surveillance, preferably with serotype data, is warranted. 
Our study has several limitations. We relied on routinely col- 
lected laboratory data, did not have detailed clinical information, 
and lacked HIV-related clinical data for some patients (those with 
only paper records). A lack of detailed clinical information limits 
our ability to apply published diagnostic algorithms to better 
differentiate between potential meningitis etiologies. 37 As most 
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records with national identiﬁcation used for HIV database linkage 
were from referral hospitals, HIV prevalence data may not be fully 
representative of the general population. HIV prevalence was likely 
under-ascertained in our study; although 73% of adults evaluated 
for meningitis were documented as HIV-infected, this is lower 
than observed in other high HIV prevalence African settings. 3,38 
This results in conservative HIV-associated meningitis incidence 
estimates. Additionally, other than years 2013–2014, we had 
incomplete CSF laboratory records and were unable to evaluate 
national incidence trends over the full study period. However, 
given stable referral pathways and health utilization reﬂected in 
the number of lumbar punctures per year, we evaluated cases 
over 2004–2014 at national referral hospitals as a crude measure 
of long-term meningitis trends. Finally, we lacked data from 2016 
including after adoption of the HIV “Treat All” strategy (with ART 
recommended regardless of CD4 count or HIV clinical stage) in 
Botswana. 14 However, the proportion of patients presenting with 
advanced HIV disease (CD4 count < 200 cells/μL) in Botswana 
has remained steady from 2015–2017 and diagnostic methods 
for suspected cases of meningitis are unchanged, 39 suggesting a 
similar epidemiology in more recent years. 
In conclusion, using a nationally representative sample of sus- 
pected meningitis cases, we provide insights into the epidemi- 
ology of meningitis in high HIV prevalence sub-Saharan African 
settings. Cryptococcal meningitis remains the predominant aeti- 
ology identiﬁed. However, our ﬁndings highlight a large burden 
of culture-negative meningitis, some of which likely represents 
partially-treated pyogenic bacterial meningitis or TB meningitis, 
but may also include a large number of other potential pathogens. 
Our ﬁndings support the need for scale-up of molecular diagnostic 
platforms, particularly for TB evaluation, and to better characterize 
meningitis aetiology to inform treatment approaches. 
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